

REMARKS/ARGUMENTS

Claims 18-30 are pending herein. Claims 1-17 have been cancelled hereby without prejudice or disclaimer, and new claims 18-33 have been added hereby. Applicants respectfully submit that support for new claims 18-33 can be found in the original specification on pages 6-8, for example, as well as the original claims, and that no new matter has been added.

1. The objection to the Abstract is noted, but deemed moot in view of the new rewritten Abstract submitted herewith. The objection to the Title is noted, but respectfully traversed for at least the reasons explained below.

37 CFR §1.72 states that the title of an invention may not exceed 500 characters in length. This is also set forth in MPEP §606. Applicants respectfully submit that the present Title is in compliance with both MPEP §606 and 37 CFR §1.72, in that the nine words in the Title describe the present invention, and because the Title does not exceed 500 characters. For at least the reasons explained above, Applicants respectfully request that the above objections be reconsidered and withdrawn.

2. The §112, second paragraph rejection of claims 1, 7 and 9 is noted, but deemed moot in view of the cancellation of those claims, and in view of new claims 18-33 submitted above (in which the language on which this rejection was based is omitted). Accordingly, Applicants respectfully request that the above rejection be reconsidered and withdrawn.

3. The §112, first paragraph rejection of claims 1, 7-9, 13 and 16 is noted, but deemed moot in view of the cancellation of those claims and in view of the new claims submitted herewith. Moreover, Applicants respectfully traverse this rejection with respect to new claims 18-33 for at least the following reasons.

Applicants respectfully submit that, in the present application, the phrase, "GLP-1(7-35) or GLP-1(7-35) having deletion, substitution and/or addition of one or a few amino acids and having a GLP-1 activity" is understood to include equivalents of the GLP-1(7-35) peptide. Applicants respectfully note that one skilled in the art would readily understand the associated structural features of each equivalent variation. The GLP-1 analog of the present invention consists of a basic GLP-1 peptide and a peptide added to the C-terminus of the

basic GLP-1 peptide. As explained in the present application, basic GLP-1 peptides include GLP-1(7-35), [Ser⁸]-GLP-1(7-35), [Gln²⁶, Asn³⁴]-GLP-1(7-35), [Ser⁸, Gln²⁶, Asn³⁴]-GLP-1(7-35), and GLP-1(7-36) of these analogs.

In the new claims submitted herewith, these basic GLP-1 peptides are recited as “a GLP-1 peptide,” which “is selected from the group consisting of GLP-1(7-35), [Ser⁸]-GLP-1(7-35), [Gln²⁶, Asn³⁴]-GLP-1(7-35), and [Ser⁸, Gln²⁶, Asn³⁴]-GLP-1(7-35).” Applicants respectfully submit that GLP-1(7-36) is contained when Waa in position 36th is Arg in the new claims, so Waa is Arg or Lys. On the other hand, the peptide added to the C-terminus of the basic GLP-1 peptide is reduced to the peptide species as elected on December 27, 2006. Therefore, Applicants respectfully submit that Waa -(Xaa)_n-Yaa means that Waa is Arg or Lys, Xaa is Lys, n is an integer of 1 to 9, and Yaa is Arg or Arg-NH₂.

For at least the reasons explained above, Applicants respectfully submit that the present specification contains an adequate written description of the presently claimed subject matter, and respectfully request that the above rejection be reconsidered and withdrawn.

4. The §102(b) rejection of claims 1, 7-11, 13 and 16 is noted, but deemed moot in view of the cancellation of those claims and in view of new claims 18-33 submitted above. Accordingly, Applicants respectfully request that the above rejection be reconsidered and withdrawn.

All claims pending herein are believed to be in condition for allowance for at least the reasons explained above, and the Applicants respectfully request that the PTO issue a Notice of Allowance for this application in due course.

If the Examiner believes that contact with Applicants' attorney would be advantageous toward the disposition of this case, the Examiner is herein requested to call Applicants' attorney at the phone number noted below.

The Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 50-1446.

Respectfully submitted,

May 29, 2007

Date



Kevin C. Brown
Reg. No. 32,402

Nicole J. Buckner
Reg. No. 51,508

KCB/NB/cmb

BURR & BROWN
P.O. Box 7068
Syracuse, NY 13261-7068

Customer No.: 025191
Telephone: (315) 233-8300
Facsimile: (315) 233-8320